A5020073368- Renal Diseases and Glomerulopathies
- Immunodeficiency and Autoimmune Disorders
- Immune Cell Function and Interaction
- Calcium signaling and nucleotide metabolism
- Protein Degradation and Inhibitors
- Systemic Lupus Erythematosus Research
- T-cell and B-cell Immunology
- Acute Myeloid Leukemia Research
- Complement system in diseases
- Pregnancy and Medication Impact
- RNA modifications and cancer
- Chronic Kidney Disease and Diabetes
- RNA Research and Splicing
- Colorectal Cancer Treatments and Studies
- Systemic Sclerosis and Related Diseases
- Adenosine and Purinergic Signaling
- Reproductive System and Pregnancy
- Monoclonal and Polyclonal Antibodies Research
- Cancer-related Molecular Pathways
- Histone Deacetylase Inhibitors Research
- Chronic Lymphocytic Leukemia Research
Amgen (United States)
2017-2021
Abstract Objective Numerous observations implicate interferon‐α (IFNα) in the pathophysiology of systemic lupus erythematosus (SLE); however, potential impact endogenous anti‐IFNα autoantibodies (AIAAs) on IFN‐pathway and disease activity is unclear. The aim this study was to characterize serologic clinical profiles AIAA‐positive patients with SLE. Methods Sera obtained from SLE (n = 49), rheumatoid arthritis 25), healthy control subjects 25) were examined for presence AIAAs, using a...
This open-label, phase 1 study evaluated the safety, pharmacokinetics, and maximum tolerated dose of AMG 232, an investigational oral, selective mouse double minute 2 homolog inhibitor in relapsed/refractory acute myeloid leukemia (AML). 232 was administered orally once daily for 7 days every weeks (7 on/off) at 60, 120, 240, 360, 480, or 960 mg as monotherapy (arm 1) 60 with trametinib 2). Dose-limiting toxicities (DLTs), adverse events (AEs), clinical pharmacodynamic response, expression...
7027 Background: The ubiquitin ligase MDM2 inhibits the tumor suppressor p53. In preclinical AML models, inhibitors have antitumor activity as monotherapy that is synergistic when combined with MEK inhibitors. This open-label phase 1b study assessed maximum tolerated dose (MTD), pharmacokinetics (PK), and preliminary of investigational oral, selective inhibitor AMG 232 or kinase trametinib in pts r/r AML. Methods: Pts received for 7 days every 2 weeks (7 on/7 off) at 60, 120, 240, 480, 960...
Felzartamab is a recombinant fully human immunoglobulin G1 anti-CD38 monoclonal antibody under clinical investigation for immune-mediated diseases. In support of felzartamab development, toxicology studies were conducted in marmoset monkeys, which was the most relevant species based on CD38 binding affinity, pharmacologic activity, and target expression. The program included an enhanced prenatal postnatal development (ePPND) study to identify potential reproductive risks. this ePPND study,...